Best Practices in NC (13.0 CME credits)


Overall Description

This On Demand activity is comprised of sessions and presentations from the Core Track of the live ASNC2017 22nd Annual Scientific Meeting September 14-17, 2017 in Kansas City, MO. The focus is to showcase current best practices when performing nuclear cardiology imaging studies that include strategies for reducing radiation dose and applications of appropriate use criteria in the clinical practice.

Activity Release Date: 10/27/2017
Activity Expiration Date: 10/26/2018
Activity Last Review Date: September 30, 2017

Statement of Need

In order to maintain competence and improve performance for best patient outcomes, imaging professionals must assimilate and integrate knowledge spanning multiple areas, including clinical data, technical aspects of imaging, and appropriate application of imaging (e.g., clinical guidelines and appropriate use criteria). Each of these areas is constantly evolving, particularly as innovative technologies and novel pharmacologic agents are introduced.

Overall Purpose:
The overall goal of this activity is to enhance physician knowledge, competence and skills in applications about appropriate use criteria, radiation safety, reporting, and lab performance in using appropriate guidelines-based treatment.

Learning Objectives:

  • Demonstrate improved skills in image interpretation and reporting
  • Learn how to recognize and minimize technical problems and artifacts that may be associated with cardiac imaging
  • Learn the appropriate use of cardiac imaging techniques based on current guidelines
  • Learn the importance of balancing radiation exposure with image quality

Target Audience

This online activity is intended for cardiologists, radiologists, nuclear medicine specialists, and other health care professionals involved in the field of nuclear cardiology.

Accreditation and Continuing Education Credit

Physicians: The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Society of Nuclear Cardiology designates this enduring activity for a maximum of 13 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASNC has achieved Accreditation with Commendation

Planners

Organizing Committee

Prem Soman, MD, PhD, FASNC, Chair
Brian G. Abbott, MD, MASNC
Firas Al Badarin, MD, FASNC
Karthikeyan Ananthasubramaniam, MD, FASNC

.

.

Timothy L. Dunn, CNMT
Raymond R. Russell, MD, PhD, FASNC
Randall C. Thompson, MD, FASNC

.

Program Committee

Donna M. Polk, MD, MPH, FASNC, Chair
Sharmila Dorbala, MD, FASNC, Vice Chair
James A. Arrighi, MD, MASNC
Rob S.B. Beanlands, MD, FASNC
Jamieson M. Bourque, MD, FASNC
Andrew J. Einstein, MD, PhD, FASNC
Oliver Gaemperli, MD
Fadi Hage, MD, FASNC
Christopher L. Hansen, MD, FASNC
Matthew E. Harinstein, MD
Gary V. Heller, MD, PhD, MASNC
Edward Hulten, MD, MPH, FASNC
Juhani Knuuti, MD, PhD
April Mann, MBA, CNMT, RT(N), NCT, FASNC
Edward J. Miller, MD, PhD, FASNC
Todd D. Miller, MD
Khurram Nasir, MD, MPH

.

Renee Bullock-Palmer, MD, FASNC
Dennis Calnon, MD, FASNC
Panithaya Chareonthaitawee, MD
Marcelo Di Carli, MD
Jane Dunne (ASNC staff)
Robert A. Pagnanelli, CNMT, RT(N)(R), FASNC
Mi-Ae Park, PhD
Matthew Parker, MD
Lawrence M. Phillips, MD, FASNC
Raymond R. Russell, III, MD, PhD, FASNC
Ibrahim M. Saeed, MD
Maria G. Sciammarella, MD
Nishant R. Shah, MD, MPH
Albert J. Sinusas, MD, FASNC
Mark I. Travin, MD, FASNC
James E. Udelson, MD, MASNC

.



Disclosure

As an Accreditation Council for Continuing Medical Education (ACCME) accredited continuing medical education (CME) provider, ASNC must insure balance, independence, objectivity, and scientific rigor in all of its continuing medical education activities. In order to achieve these goals, we require everyone who is in a position to control the content of an educational activity to disclose to us all relevant financial relationships with any commercial interest. These relationships are those in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected. We also consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. With respect to personal financial relationships, ‘contracted research’ includes research funding where the institution receives the grant and manages the funds and the person is the principal or named investigator on the grant. Relevant financial relationships are financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship a planner or a speaker may have, it will be resolved prior to the activity. ASNC also requires that all faculty presenters disclose their intent to discuss any unlabeled/unapproved uses of drugs and/or devices during their presentations.

1 designates presenter
2 designates peer reviewer/moderator
3 designates planner

The following individuals have stated that they have no relevant financial relationships with any commercial interest that produces health care goods or services, including computer software/hardware, related to the content of the educational presentation in which they are involved:

1,2Abbott, Brian
1,2,3Ananthasubramaniam, Karthik
1,2,3Arrighi, James
1,3Arumugam, Parthiban
1Askew, John Wells
1,3Bokhari, Sabahat
1,2,3Bourque, Jamieson
1,2,3Bullock-Palmer, Renee
1,2,3Chareonthaitawee, Panithaya
1,3Cohen, Mylan

1,3Cremer, Paul
1,2,3Dunn, Timothy
2Dunne, Jane
2Gaemperli, Oliver
1Gerson, Myron
1Gould, K. Lance
1,2Harinstein, Matthew
1,2,3Heller, Gary
1,3Holly, Thomas
1,2Hulten, Edward
1,3Hyun, Mark
1,3Iskandrian, Ami

2Knuuti, Juhani
1,3Leppo, Jeffrey
1,3McGhie, A. Iain
1,3Miller, Todd
2Nasir, Khurram
1Oakes, Lisa
1,2Park, Mi-Ae
1Parker Ward, R.
1,2,3Phillips, Lawrence
1,2,3Polk, Donna
1,2,3Saeed, Ibrahim
1,3Schockling, Eric

1,3Sciammarella, Maria

1,2Sinusas, Albert
1,3Skali, Hicham
1,3Taqueti, Viviany
1,2,3Thompson, Randall
1,3Tilkemeier, Peter
1,2,3Travin, Mark
1,3Van Decker, William
1,3Verberne, Hein
1,3Wann, L Samuel

.

.

Relevant financial relationships with commercial interests have been stated as noted by the following planners, presenters and moderators:

2Al Badarin, Firas
Speakers Bureau: Lantheus

1Alexander, Kevin
Research Grant or Contractor: Principal investigator for an investigator-initiated research grant from Pfizer (2017 ASPIRE Transthyretin Amyloidosis Competitive Research Grant Award)

2Beanlands, Rob
Consulting Fee: Lantheus Medical Imaging Jubilant DRAXImage
Research Grant or Contractor: Lantheus Medical Imaging Jubilant DRAXImage, GE Healthcare

1,2,3Calnon, Dennis
Consulting Fee: Navidea Biopharmaceuticals
Research Grant or Contractor:

1Case, James
Intellectual Property Rights: CVIT
Research Grant or Contractor: Astellas, General Electric
Stock Interest: CVIT
Salaried Employee: CVIT

1,2Di Carli, Marcelo
Research Grant or Contractor: Spectrum Dynamics
Advisory Board: Sanofi

1,2,3Dorbala, Sharmila
Research Grant or Contractor: Astellas
Stock Interest: General Electric

1,3Doukky, Rami
Research Grant or Contractor: Astellas
Advisory Board: Astellas


1Duvall, W. Lane
Research Grant or Contractor: Physician initiated study grant - Astellas

1,2,3Einstein, Andrew
Consulting Fee: GE Healthcare
Research Grant or Contractor: Philips, Toshiba

1,3Garcia, Ernest
Intellectual Property Rights: Emory cardiac toolbox (ECTb)
Consulting Fee: Syntermed
Research Grant or Contractor: SyntermedRoyalty: Royalties for ECTb
Stock Interest: Shares of syntermed

1,3Gropler, Robert
Consulting Fee: Sanofi
Research Grant or Contractor: Bayer, NIH, Biomedical

1,2Hage, Fadi
Research Grant or Contractor: Astellas, Novartis

1,2,3Hansen, Christopher
Consulting Fee: Digirad
Royalty: General Electric

1,3Hendel, Robert
Consulting Fee: Astellas Pharma
Speakers Bureau: Astellas Pharma

1Hundley, W. Gregory
Intellectual Property Rights: Prova
Stock Interest: Prova

1Maddahi, Jamshid
Consulting Fee: Lantheus Medical Imaging, Astellas
Research Grant or Contractor: Lantheus Medical Imaging
Speakers Bureau: Astellas

2,3Mann, April
Advisory Board: Astellas Pharma USA

1,2,3Miller, Edward
Consulting Fee: GE, Inc
Research Grant or Contractor: Bracco, Inc

1,2,3Pagnanelli, Robert
Speakers Bureau: Astellas

1,3Parker, Matthew
Consulting Fee: Intersocietal Accreditation Commission-PET/Nuclear peer review

1,3Poornima, Indu
Speakers Bureau: Astellas

1Ruberg, Frederick
Consulting Fee: Caelum Biosciences, Prothena, Alnylam Pharmaceuticals

1,2,3Russell, Raymond
Stock Interest: Novartis (spouse)
Salaried Employee: Novartis (spouse)

1,3Shah, Nishant
Stock Interest: General Electric

1,2,3Soman, Prem
Research Grant or Contractor: Astellas
Advisory Board: Alnylam Pharma

1Tawakol, Ahmed
Research Grant: Genentech, Actelion
Consultant: Actelion

1,2,3Udelson, James
Advisory Board: Lantheus

1,3Winchester, David
Research Grant or Contractor: Roche Diagnostics

.

.

Disclaimer
The information in this activity represents the opinion of the faculty and is not necessarily the official position of ASNC.

Policy on Off Label Use

Presentations may include discussion of drugs or devices, or uses of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASNC is committed to the free exchange of medical education. Inclusion of any discussion in this program, including discussion on off-label uses, does not imply an endorsement by ASNC of the uses, products or techniques presented. Presenters are required to disclose to the learners, if there is any off-label usage within the presentation.

Method of Participation and CME Certificates
To receive CME credit for this product, you must:

  1. Purchase the product.
  2. Read the CME front matter.
  3. View the session(s) of your choosing.
  4. Click the CE Information tab on individual sessions, and the Test button.
  5. Complete the post-test. Your must score 75% to earn credit. You may take the test as many times as you need to score 75%.
  6. When you are finished watching the session of your choosing, your certificate will reflect the total accumulated credits from the session. Generate and print your CME certificate.
  7. If you would like a transcript, or a breakdown of all credits claimed across all the ASNC2017 content, visit the My Account area and click on the tab on the left labeled Certificates and Transcripts. As you take more sessions, this transcript will automatically update with the additional credtis.

Estimated time to complete this activity 13 hours.

Medium or Combination of Medium Used:
This is an on demand activity with slides synchronized with audio.

Commercial Acknowledgement
This activity has not received commercial support

Hardware/Software Requirements
For the most current list of system requirements, please visit http://asnc.digitellinc.com/asnc/support/faq

For technical support please contact:

support@digitellinc.comor (716)338-0332 ; Toll Free (877)796-1325 (U.S.A. only)

ASNC Contact Information:

American Society of Nuclear Cardiology
4340 East-West Highway, Suite 1120
Bethesda, MD 20814-4578
Phone: (301) 215-7575
Fax: (301) 215-7113
info@asnc.org

Privacy Policy

This website is provided by Digitell Inc. We do not share information about individuals with anyone other than the credit card processors and the shipping company.

The complete Privacy Policy can be found by clicking Privacy Policy at the bottom of http://asnc.digitellinc.com/asnc.

Standard: $350.00
Members: $250.00

Products

How to Incorporate Test Findings Beyond Perfusion

Preview Available

How to Incorporate Test Findings Beyond Perfusion

Sep 14, 2017 1:00pm ‐ Sep 14, 2017 2:30pm

Credits: None available.

Learning Objectives:

  • Recognize the value of non-imaging stress test variables including abnormal heart rate responses associated with exercise and exercise hypotension
  • Be better able to manage patients who have a positive EKG and normal MPI after stress testing

13:00 - 13:20 - Significant ST Segment Changes

13:20 - 13:40 - Arrhythmias, Heart Rate Recovery and Abnormal Hemodynamic Responses

13:40 - 14:00 - High Risk MPI Markers

14:00 - 14:20 - Coronary Artery Calcium and Coronary Flow Reserve

14:20 - 14:30 - Discussion

Moderator(s): Speaker(s):
Tags: Core

Nuclear Cardiology Laboratory in 2017

Preview Available

Nuclear Cardiology Laboratory in 2017

Sep 15, 2017 10:30am ‐ Sep 15, 2017 12:00pm

Credits: None available.

Learning Objectives:

  • Understand basic overview of attenuation correction, the potential pitfalls and how to optimise practice
  • Attendees will learn sources of radiation in Cardiac PET, SPECT and CT
  • Attendees will review the principles of ALARA and how to apply them to diagnostic testing
  • Attendees will learn practical strategies for reducing patient and staff radiation dose based on nationally and internationally recognized standards

10:30 - 10:45 - ImageGuide: How it can Improve Your Practice

10:45 - 11:00 - ALARA: Practical Approaches to Radiation Reduction

11:00 - 11:15 - Lab Accreditation: Nuts and Bolts

11:15 - 11:30 - Optimizing Attenuation Correction and Reconstruction

11:30 - 11:45 - Advances in Nuclear Camera Technology

11:45 - 12:00 - Discussion

Moderator(s): Speaker(s):
Tags: Core

Cardiac Amyloidosis in 2017

Preview Available

Cardiac Amyloidosis in 2017

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

Learning Objectives:

  • Understand the complementary role of echocardiography and cardiac magnetic resonance imaging for the diagnostic and prognostic evaluation of patients with cardiac amyloidosis

10:30 - 10:50 - Pathogenesis of Amyloidosis

10:50 - 11:10 - What's New and What's on the Horizon in Diagnosis and Treatment

11:10 - 11:30 - Echocardiography and MRI in Amyloidosis

11:30 - 11:50 - Common and Uncommon Findings of PYP Imaging with Cases

11:50 - 12:00 - Discussion

Moderator(s): Speaker(s):
Tags: Core

Imaging for the Detection or Risk Assessment of Stable Coronary Artery Disease: Get with the Guidelines

Preview Available

Imaging for the Detection or Risk Assessment of Stable Coronary Artery Disease: Get with the Guidelines

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

Learning Objectives:

  • Enable the attendee to draw from established guidelines and appropriate use criteria when using non-invasive imaging for patient risk assessment following percutaneous coronary intervention
  • Determine the benefit of revascularization with use of ischemic myocardial burden percent of ischemia

10:30 - 12:00 - Case Presenters

Moderator(s):
  • Rami Doukky, MD, FASNC, Cook County Health and Hospitals System
  • Nishant Shah, MD, MPH, Alpert Medical School of Brown University
Speaker(s):
Tags: RWTE

Patient Centered Myocardial Perfusion Imaging

Preview Available

Patient Centered Myocardial Perfusion Imaging

Sep 16, 2017 1:30pm ‐ Sep 16, 2017 3:00pm

Credits: None available.

Learning Objectives:

  • At the conclusion of the presentation, the learner will have greater understanding of the clinical impact of the final report and steps that can be taken to improve communication with the referring physician/nurse practitioner/physician assistant.
  • Understand that various protocol options are available besides just a rest-stress SPECT protocol which may be better suited for individual patients

13:30 - 13:50 - Appropriate Use: Are we Making Progress?

13:50 - 14:10 - Personalized Protocol Selection

14:10 - 14:30 - Optimizing the Clinical Value of Report

14:30 - 14:50 - Current Health Policy Issues: Implications for Patient Choice and Costs

14:50 - 15:00 - Discussion

Moderator(s): Speaker(s):
Tags: Core

Viability Assessment (SPECT and PET)

Preview Available

Viability Assessment (SPECT and PET)

Sep 16, 2017 1:30pm ‐ Sep 16, 2017 3:00pm

Credits: None available.

Learning Objectives:

  • Understand perfusion and metabolism patterns in myocardial scar, hibernation, ischemic memory, and Takotsubo cardiomyopathy

13:30 - 15:00 - Case Presenters

Moderator(s): Speaker(s):
Tags: RWTE

Nuclear Cardiology Beyond Plain Myocardial Perfusion Imaging

Preview Available

Nuclear Cardiology Beyond Plain Myocardial Perfusion Imaging

Sep 16, 2017 1:30pm ‐ Sep 16, 2017 3:00pm

Credits: None available.

Learning Objectives:

  • Demonstrate improved skills in image interpretation and reporting

13:30 - 14:00 - PYP Imaging in Amyloidosis: Acquisition and Quantitation

14:00 - 14:30 - Myocardial Blood Flow with SPECT: Acquisition and Quantitation

14:30 - 15:00 - Translational Tracers for Nuclear Cardiology

Moderator(s): Speaker(s):

Controversies in Clinical Cardiology and Cardiac Imaging

Preview Available

Controversies in Clinical Cardiology and Cardiac Imaging

Sep 17, 2017 8:00am ‐ Sep 17, 2017 9:30am

Credits: None available.

Learning Objectives:

  • Understand that in 4000 sequential cardiac PETs, the Coronary Flow Capacity combining stress perfusion and CFR uniquely identifies patients for whom PCI/CABG significantly reduces MI and mortality by 54% over long term follow up and eliminates 70% to 90% of low benefit invasive procedures or other tests including patients with known or advanced CAD with low risk disease by PET that are optimally treated medically
  • To become familiar with the etiology of LV ejection fraction decline in patients receiving cardiotoxic chemotherapy

08:00 - 08:12 - Debate 1 - Breakthrough: Novel approaches for Early Detection of Chemotherapy Cardiotoxicity

08:12 - 08:24 - Debate 1 - Controversy: What Would it take for Novel Markers of Cardiac Toxicity to Replace Ejection Fraction

08:24 - 08:30 - Discussion

08:30 - 08:42 - Debate 2 - Breakthrough: FDG Imaging of Cardiac and Vascular Inflammation

08:42 - 08:54 - Debate 2 - Controversy: Is FDG Imaging the Be-all and End-all?

08:54 - 09:00 - Discussion

09:00 - 09:12 - Debate 3 - Breakthrough: Noninvasive Quantification of Coronary Flow Reserve

09:12 - 09:24 - Debate 3 - Controversy: Is Coronary Flow Reserve Good Enough to Guide Management in CAD?

09:24 - 09:30 - Discussion

Moderator(s): Speaker(s):
Tags: Plenary

How Does Radionuclide Imaging Guide Clinical Decision Making?

Preview Available

How Does Radionuclide Imaging Guide Clinical Decision Making?

Sep 17, 2017 11:00am ‐ Sep 17, 2017 12:00pm

Credits: None available.

Learning Objectives:

  • Be aware of the appropriate and rarely appropriate use of nuclear cardiology stress testing

11:00 - 11:20 - How to Decide When to Proceed to Angiography

11:20 - 11:40 - Latest in Viability Assessment

11:40 - 12:00 - Preoperative Testing: When is Preoperative Evaluation Helpful

Moderator(s): Speaker(s):
Tags: Core